Christopher Starr
Gründer bei MONOPAR THERAPEUTICS INC.
Vermögen: 47 190 $ am 30.04.2024
Profil
Christopher M.
Starr is the founder of Horizon Pharmaceutical LLC (founded in 2009), Monopar Therapeutics, Inc. (founded in 2014), BioMarin Pharmaceutical, Inc. (founded in 1997), and Raptor Pharmaceuticals Corp.
(founded in 2005).
He holds the title of Independent Director at Horizon Pharmaceutical LLC from 2015 to 2016, Executive Chairman at Monopar Therapeutics, Inc. from 2014 to present, and Chief Scientific Officer & Senior Vice President at BioMarin Pharmaceutical, Inc. He also served as a Director at Raptor Pharmaceuticals Corp.
from 2014 to 2016.
Dr. Starr's current job(s) include being the Chief Executive Officer at Raptor Discoveries, Inc. since 2005, Chairman at Thiogenesis Therapeutics, Inc., Chairman at Thiogenesis Therapeutics Corp.
since 2022, and Director at Glycomine, Inc. since 2016.
His former job(s) include being the Vice President-Research & Development at Glyko, Inc. from 1991 to 1998.
He also worked as an Associate at The National Research Council and National Institutes of Health.
Dr. Starr's education history includes a doctorate degree from SUNY Upstate Medical University and an undergraduate degree from Syracuse University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MONOPAR THERAPEUTICS INC
0,43% | 08.03.2024 | 75 263 ( 0,43% ) | 47 190 $ | 30.04.2024 |
| 08.12.2022 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Christopher Starr
| Unternehmen | Position | Beginn |
|---|---|---|
| MONOPAR THERAPEUTICS INC. | Gründer | 01.12.2014 |
| THIOGENESIS THERAPEUTICS, CORP. | Vorsitzender | 31.03.2022 |
| Raptor Discoveries, Inc. | Vorstandsvorsitzender | 08.09.2005 |
Glycomine, Inc.
 Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Direktor/Vorstandsmitglied | 01.06.2016 |
Ehemalige bekannte Positionen von Christopher Starr
| Unternehmen | Position | Ende |
|---|---|---|
| RAPTOR PHARMACEUTICAL CORP | Gründer | 25.10.2016 |
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Gründer | 01.10.2016 |
| BIOMARIN PHARMACEUTICAL INC. | Gründer | 01.01.2006 |
Glyko, Inc.
 Glyko, Inc. Medical SpecialtiesHealth Technology Part of BioMarin Pharmaceutical, Inc., Glyko, Inc. discovers, develops, and commercializes carbohydrate enzyme therapeutics. The company is based in Novato, CA. Glyko was acquired by BioMarin Pharmaceutical, Inc. on October 08, 1998 for $14.50 million. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1998 |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
Ausbildung von Christopher Starr
| SUNY Upstate Medical University | Doctorate Degree |
| Syracuse University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| MONOPAR THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Glyko, Inc.
Glyko, Inc. Medical SpecialtiesHealth Technology Part of BioMarin Pharmaceutical, Inc., Glyko, Inc. discovers, develops, and commercializes carbohydrate enzyme therapeutics. The company is based in Novato, CA. Glyko was acquired by BioMarin Pharmaceutical, Inc. on October 08, 1998 for $14.50 million. | Health Technology |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
The National Research Council
 The National Research Council Miscellaneous Commercial ServicesCommercial Services The National Research Council provides science, technology and health policy consulting and advice. The company was founded in 1916 and is headquartered in Washington, DC. | Commercial Services |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
| Raptor Discoveries, Inc. | |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Health Technology |
| Thiogenesis Therapeutics Corp. |
